CLX Medical

CLX Medical, Inc. is a healthcare company that historically specialized in the distribution of medical diagnostic products and screening services. The company's primary focus was the commercialization of the FibroSpect II test, a non-invasive blood-based diagnostic tool designed to assess the severity of liver fibrosis in patients with chronic Hepatitis C. By utilizing a proprietary algorithm to analyze specific biomarkers, the test provided an alternative to traditional liver biopsies. Headquartered in Scottsdale, Arizona, the company aimed to expand its portfolio within the diagnostic space but has since ceased active operations. CLX Medical is currently classified as a shell entity and is traded on the OTC Markets under the symbol CLXM.